Core Viewpoint - Aoxing Life Science Technology (06118) has seen a significant stock price increase, with a rise of over 54% towards the end of trading, currently up 48.04% at HKD 1.51, with a trading volume of HKD 8.4778 million [1] Company Overview - Aoxing Group is a technology-based pharmaceutical engineering solution provider based in Hong Kong [1] - The business of Aoxing Life Science includes nine segments: sterile drug production contamination control consumables, equipment and services, environmental monitoring and testing systems, validation and single equipment, biological upstream process systems, disposable process systems, laboratory information technology, and life science consulting [1] Financial Performance - Aoxing Life Science reported a mid-term profit attributable to shareholders of HKD 24.999 million, representing a year-on-year increase of 325.37% [1]
港股异动 | 奥星生命科技(06118)尾盘涨超54% 奥星集团为科技型制药工程解决方案提供商